Patients in the C2 subgroup, with an enrichment in ECT1 (immuno-suppressive), ECT3 (plasma cells) and ECT10 (TREM2+ TAM, Wound-myCAF), were mainly composed of Basal-like TN (31.5%), Lum B (31.7%) and HER2 (23%) BC subtypes and showed the worst survival, as expected. The gene discussed is FGFR2; the disease is breast cancer.